Matthew Hohenboken
About
Matthew Hohenboken is a scholar working on Epidemiology, Infectious Diseases and Immunology.
According to data from OpenAlex, Matthew Hohenboken has authored 27 papers receiving a total of 422 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Epidemiology, 10 papers in Infectious Diseases and 7 papers in Immunology. Recurrent topics in Matthew Hohenboken's work include Influenza Virus Research Studies (19 papers), Respiratory viral infections research (13 papers) and SARS-CoV-2 and COVID-19 Research (6 papers). Matthew Hohenboken is often cited by papers focused on Influenza Virus Research Studies (19 papers), Respiratory viral infections research (13 papers) and SARS-CoV-2 and COVID-19 Research (6 papers). Matthew Hohenboken collaborates with scholars based in United States, Germany and Australia. Matthew Hohenboken's co-authors include Howard S. Tager, J. Markese, Robert J. Dinerstein, Niranjan Kanesa-thasan, Stephan Bart, Vas Narasimhan, Philip R. Dormitzer, Giovanni Della Cioppa, Thomas R. Talbot and Kathryn M. Edwards and has published in prestigious journals such as Proceedings of the National Academy of Sciences, PEDIATRICS and Endocrinology.
In The Last Decade
Matthew Hohenboken
26 papers receiving 394 citations
Peers
Matthew Hohenboken
Sheila Hickey United States
Ivana Grgić Croatia
Dennis Morrison United States
C. R. Gregg United States
J Rotta Czechia
Owais Khan United States
Tiffany Hensley‐McBain United States
A Wegmann Switzerland
Jennifer A. Manuzak United States
Ronald B. Moss United States
Citations per year, relative to Matthew Hohenboken Matthew Hohenboken (= 1×)
peers
Sheila Hickey
Countries citing papers authored by Matthew Hohenboken
Since
Specialization
Citations
This map shows the geographic impact of Matthew Hohenboken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Hohenboken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Hohenboken more than expected).
Fields of papers citing papers by Matthew Hohenboken
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Matthew Hohenboken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Hohenboken. The network helps show where Matthew Hohenboken may publish in the future.
Co-authorship network of co-authors of Matthew Hohenboken
This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Hohenboken. A scholar is included among the top collaborators of Matthew Hohenboken based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Hohenboken. Matthew Hohenboken is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Giles, Michelle, Carmen Baccarini, Paul Nguyen, et al.. (2025). Immunogenicity and safety of self-amplifying mRNA COVID-19 vaccine (ARCT-2303), with or without co-administration of seasonal inactivated influenza vaccine in adults: a phase 3, randomised, controlled, observer-blind, multicentre study. EClinicalMedicine. 87. 103428–103428.
2.
Põder, Airi, Jay Meyer, Peter Heymer, et al.. (2023). Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age. Vaccines. 11(10). 1528–1528.
3.
Versage, Eve, et al.. (2023). Antibody responses against heterologous H5N1 strains for an MF59-adjuvanted cell culture–derived H5N1 (aH5n1c) influenza vaccine in adults and older adults. Human Vaccines & Immunotherapeutics. 19(1). 2193119–2193119.
4.
Oberyé, Janine, Jessica D. Albano, Hugh H. Tilson, et al.. (2022). A Prospective Cohort Study on Pregnancy Outcomes of Persons Immunized with a Seasonal Quadrivalent Inactivated Influenza Vaccine during Pregnancy. Vaccines. 10(10). 1577–1577.
5.
Peterson, James T., et al.. (2022). Phase 3 Randomized, Multicenter, Placebo-Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects. Vaccines. 10(4). 497–497.
6.
Chanthavanich, Pornthep, et al.. (2021). Antibody responses against heterologous A/H5N1 strains for an MF59-adjuvanted cell culture–derived A/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects. Vaccine. 39(47). 6930–6935.
7.
Versage, Eve, et al.. (2021). Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults. Vaccines. 9(12). 1468–1468.
8.
Frey, Sharon E., Sepehr Shakib, Pornthep Chanthavanich, et al.. (2019). Safety and Immunogenicity of MF59-Adjuvanted Cell Culture–Derived A/H5N1 Subunit Influenza Virus Vaccine: Dose-Finding Clinical Trials in Adults and the Elderly. Open Forum Infectious Diseases. 6(4). ofz107–ofz107.
9.
Abdelnour, Arturo, Nan‐Chang Chiu, Cheng‐Hsun Chiu, et al.. (2014). Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: Results of an open-label, randomized, phase 3b controlled study in healthy infants. Vaccine. 32(8). 965–972.
10.
Johnson, Casey, et al.. (2014). Safety and Immunogenicity of Cell Culture-Derived A/H3N2 Variant Influenza Vaccines: A Phase I Randomized, Observer-Blind, Dose-Ranging Study. The Journal of Infectious Diseases. 212(1). 72–80.
11.
Bart, Stephan, Matthew Hohenboken, Giovanni Della Cioppa, et al.. (2014). A Cell Culture–Derived MF59-Adjuvanted Pandemic A/H7N9 Vaccine Is Immunogenic in Adults. Science Translational Medicine. 6(234). 234ra55–234ra55.
12.
Nolan, Terry, Michael D. Nissen, Lisa Bedell, et al.. (2013). Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age. Human Vaccines & Immunotherapeutics. 10(2). 280–289.
13.
Henry, Dan, et al.. (2012). Identification of Antigen and Adjuvant Doses Resulting in Optimal Immunogenicity and Antibody Persistence up to 1 Year After Immunization With a Pandemic A/H1N1 Influenza Vaccine in Children 3 to <9 Years of Age. The Pediatric Infectious Disease Journal. 31(4). e59–e65.
14.
Henry, Dan, et al.. (2012). Identification of Antigen and Adjuvant Doses Resulting in Optimal Immunogenicity and Antibody Persistence up to One Year After Immunization with a Pandemic A/H1N1 Influenza Vaccine in Children 3 to < 9 Years of Age. The Pediatric Infectious Disease Journal. 1–1.
15.
Tsai, Theodore F., Paola Pedotti, Anne Katrin Hilbert, et al.. (2010). Regional and age-specific patterns of pandemic H1N1 influenza virus seroprevalence inferred from vaccine clinical trials, August-October 2009. Eurosurveillance. 15(30).
16.
Creech, C. Buddy, et al.. (2009). Vaccination as infection control: A pilot study to determine the impact of Staphylococcus aureus vaccination on nasal carriage. Vaccine. 28(1). 256–260.
17.
Li, Yanhong, Matthew Hohenboken, Robert I. Griffiths, et al.. (2009). Outcomes of Staphylococcus aureus Infection in Hemodialysis-Dependent Patients. Clinical Journal of the American Society of Nephrology. 4(2). 428–434.
18.
Rennels, Margaret B., Matthew Hohenboken, Keith S. Reisinger, et al.. (1998). COMPARISON OF ACELLULAR PERTUSSIS-DIPHTHERIA-TETANUS TOXOIDS AND HAEMOPHILUS INFLUENZAE TYPE B VACCINES ADMINISTERED SEPARATELYVS. COMBINED IN YOUNGER VS. OLDER TODDLERS. The Pediatric Infectious Disease Journal. 17(2). 164–166.
19.
Goepp, Julius G., Matthew Hohenboken, Janné Almeido-Hill, & Mathuram Santosham. (1992). Persistent urinary antigen excretion in infants vaccinated with Haemophilus influenzae type b capsular polysaccharide conjugated with outer membrane protein from Neisseria meningitidis. The Pediatric Infectious Disease Journal. 11(1). 2–5.
20.
Tager, Howard S., Matthew Hohenboken, & J. Markese. (1977). High Titer Glucagon Antisera. Endocrinology. 100(2). 367–372.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Sheila Hickey Breakdown of academic impact, for papers by Ivana Grgić Breakdown of academic impact, for papers by Dennis Morrison Breakdown of academic impact, for papers by C. R. Gregg Breakdown of academic impact, for papers by J Rotta Breakdown of academic impact, for papers by Owais Khan Breakdown of academic impact, for papers by Tiffany Hensley‐McBain Breakdown of academic impact, for papers by A Wegmann Breakdown of academic impact, for papers by Jennifer A. Manuzak Breakdown of academic impact, for papers by Ronald B. Moss